PDCD1 and melanoma: Worth specific mentioning are two clinical studies of T-VEC with either anti-PD-1 or anti-CTLA-4 antibodies, achieving dramatically improved clinical responses with up to ~ 67% objective response rate in patients with advanced melanoma [55, 105].